Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: Selective expression of early activation markers

Journal of Immunology

Volumn 156, Issue 9, 1996, Pages 3486-3492

  Coventry, Brendon J ^a   Weeks, Sandy C ^b   Heckford, Susan E ^b   Sykes, Pamela J ^b   Bradley, John ^b   Skinner, John M ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD69 ANTIGEN; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LEUKOSIALIN; MESSENGER RNA; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS; RNA TRANSCRIPTION; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; IN SITU HYBRIDIZATION; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 0029882174     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Von Kleist, S., J. Berling, W. Bohle, and C. Wittekind. 1987. Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. Int. J. Cancer 40:18.
2. An, T., U. Sood, T. Pietru, G. Cummings, K. Hashimoto, and J. D. Crissman. 1987. In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Am. J. Pathol. 128:52.
3. + cells in the tumor stroma. Int. J. Cancer 35:199.
4. Baxevanis, C. N., G. V. Dedoussis, N. G. Papodopoulos, and I. Missitzis. 1994. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74:1275.
5. Fossatti, G., A. Anichini, D. Taramelli, A. Balsari, C. Gambacorti- Passerini, J. M. Kirkwood, and G. Parmiani. 1986. Immune response to autologous human melanoma: implication of class I and class II MHC products. Biochim. Biophys. Acta 865:235.
6. Parmiani, G. 1990. An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol. Today 11:113.
7. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. a. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233:1318.
8. Rosenberg, S. A., and M. T. Lotze. 1986. b. Cancer immunotherapy using interleukin 2 and interleukin 2 activated killer cells. Annu. Rev. Immunol. 4:681.
9. Rosenberg, S. A., M. T. Lotze, L. M. Muul, A. E. Chang, F. P. Avis, S. Leitman, W. M. Linehan, C. N. Robertson, R. E. Lee, J. T. Rubin, C. A. Seipp, C. G. Simpson, and D. E. White. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 or high dose interleukin 2 alone. N. Engl. J. Med. 316:889.
10. Miescher, S., T. L. Whiteside, S. Carrel, and V. von Fliedner. 1986. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid rumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 136:1899.
11. Cohen, P. J., M. T. Lotze, J. R. Roberts, S. A. Rosenberg, and E. S. Jaffe. 1987. The immunopathology of sequential tumor biopsies in patients treated with interleukin 2. Am. J. Pathol. 129:208.
12. Ralfkiaer, E., K. C. Hou-Jensen, K. Gatter, K. T. Drzewiecki, and D. Y. Mason. 1987. Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas. Virchows Arch. 410:355.
13. Brocker, E. B., G. Zwadlo, B. Holzmann, E. Macher, and C. Sorg. 1988. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int. J. Cancer 41:562.
14. Jackson, D. G., and J. I. Bell. 1990. Isolation of a cDNA encoding the human CD38(T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J. Immunol. 144:2811.
15. Schwarting, R., G. Niedobitek, and H. Stein. 1990. Cluster report: CD69. Fourth International Leukocyte Typing Workshop, Vienna, Austria. Oxford University Press, Oxford, pp. 428-432 (Abstr. A4).
16. Stein, H., R. Schwarting, G. Niedobitek, and F. Dallenbach. 1990. Activation Section Report. Fourth International Leukocyte Typing Workshop, Vienna, Austria, Vol. 5. Oxford University Press, Oxford, pp. 398-400.
17. Williams, J. M., V. E. Kelley, R. L. Kirkman, N. L. Tilney, M. E. Shapiro, J. R. Murphy, and T. B. Strom. 1988. T cell activation antigens: therapeutic implications. Immunol. Invest. 16:687.
18. Mackie, J. D., O. G. Pankewycz, R. Hassarjian, J. R. Murphy, V. E. Kelley, and T. B. Strom. 1989. Immunotherapy using interleukin-2 diphtheria toxin chimer prolongs murine allografts. Transplant. Proc. 21:2718.
19. Kirkman, R. L., M. E. Shapiro, C. B. Carpenter, E. L. Milford., E. L. Ramos, N. L. Tilney, T. A. Waldmann, C. E. Zimmerman, and T. B. Strom. 1989. Early experience with anti-Tac in clinical renal transplantation. Transplant. Proc. 21: 1766.
20. Lotze, M. T., M. C. Custer, S. O. Sharrow, L. A. Rubin, D. L. Nelson, and S. A. Rosenberg. 1987. In-vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res. 47:2188.
21. Lotze, M. T., and O. J. Finn. 1990. Recent advances in cellular immunology: implications for immunity to cancer. Immunol. Today 11:190.
22. Zola, H., L. Flego, P. J. MacArdle, P. J. Donohoe, J. Ranford, D. Roberton. 1992. The CD45RO (p180, UCHL1) marker: complexity of expression in peripheral blood. Cell. Immunol. 145:175.
23. Spits, H., and R. de Waal Malefyt. 1992. Functional characterisation of human IL-10. Int. Arch. Allergy Immunol. 99:8.
24. Cosulich, M. E., A. Risso, M. R. Mazza, D. Smilovich, M. C. Capra, A. Massa, S. Costanzi, I. Baldissarro, W. Droge, and A. Bargellesi. 1989. Functional and biochemical characterisation of the activation CD69 antigen defined by A40 (MLR3) mAb. In Leucocyte Typing IV: White Cell Differentiation Antigens. W. Knapp, B. Dorken, E. P. Rieber, H. Stein, W. R. Gilks, R. E. Schmidt, and A. E. G. Kr. von dem Borne, eds. Oxford University Press, Oxford, pp. 432-435.
25. Akbar, A. N., L. Terry, A. Timms, P. C. Beverley, and G. Janossy. 1988. Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J. Immunol. 140:2171.
26. Warren, H. S., and L. J. Skipsey. 1991. Loss of activation-induced CD45RO with maintenance of CD45RA expression during prolonged culture of T cells and NK cells. Immunology 74:78.
27. + cells. J. Immunol. 126:1393.
28. Rubin, L. A., C. C. Kurman, W. E. Biddison, N. D. Goldman, and D. L. Nelson. 1985. A monoclonal antibody 7G7/B6 binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognised by IL-2 or anti-Tac. Hybridoma 4:91.
29. Adams, J. C. 1981. Heavy metal intensification of DAB-based HRP reaction product. J. Histochem. Cytochem. 29:775.
30. Coventry, B. J., S. H. Neoh, B. X. Mantzioris, J. M. Skinner, H. Zola, and J. Bradley. 1994. Comparison of the sensitivity of immunoperoxidase staining methods with high sensitivity fluorescence flow cytometry-antibody quantitation on the cell surface. J. Histochem. Cytochem. 42:1143.
31. Devos, R., G. Plaetinck, H. Cheroutre, G. Simons, W. Degrave, J. Tavernier, E. Remaut, and W. Fiers. 1993. Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res. 11:4307.
32. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1982. Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
33. Dunnill, M. S. 1968. Quantitative methods in histology. In Recent Advances in Clinical Pathology. S. C. Dyke, ed. Churchill Livingstone, London, pp. 401-416.
34. SPSS for Windows: Professional Statistics. 1993. Release 6.0, SPSS, Inc., Chicago.
35. Yang, J. C. 1994. Cellular immunotherapy of cancer. In Current Opinion in General Surgery. J. Daly, ed. Current Science, Philadelphia, pp. 238-244.
36. Hamaoka, T., and H. Fujiwara. 1987. Phenotypically and functionally distinct T-cell subsets in anti-tumour responses. Immunol. Today 8:267.
37. Stoll, M., R. Dalchau, and R. E. Schmidt. 1990. Cluster report: CD43. In Fourth International Leukocyte Typing Workshop, Vienna, Austria. Oxford University Press, Oxford, pp. 604-608 (Abstr. N5).
38. Axelsson, B., M. Wike'n, and M. Vargas-Cortes. 1990. Effect of CD43 antibody B1-B6 on T-, B-, and NK-cell function. Fourth International Leukocyte Typing Workshop, Vienna, Austria. Oxford University Press, Oxford, pp. 617-619 (Abstr. N5.5).
39. Miller, J. F. A. P. 1990. Tolerant T-cells in transgenic mice. In Proceedings of the International Conference on Biological Agents in the Treatment of Melanoma and Other Cancers. P. Hersey, ed. N.S.W. Govt. Printer, Newcastle, Australia; pp. 150-157.
40. Beverly, B., S.-M. Kang, M. J. Lenardo, and R. H. Schwartz. 1992. Reversal of in vitro T cell clonal anergy by EL-2 stimulation. Int. Immunol. 4:661.
41. Schwartz, E. M., P. Salgame, and B. R. Bloom. 1993. Molecular regulation of human interleukin 2 and T-cell function by interleukin 4. Proc. Natl. Acad. Sci. USA 90:7734.
42. + T-cell clones and resting T-cells: specific inhibition of IL-2 production and proliferation. J. Immunol. 150:4754.
43. Vitolo, D., T. Zerbe, A. Kanbour, C. Dahl, R. B. Herberman, and T. L. Whiteside. 1992. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int. J. Cancer 51:573.
44. Granelli-Piperno, A. 1988. In situ hybridisation for imerleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J. Exp. Med. 168:1649.
45. Yssel, H., R. de Waal Malefyt, M.-G. Roncarolo, J. S. Abrams, R. Lahesmaa, H. Spits, and J. E. de Vries. 1992. IL-10 is produced by subsets of human CD4 T cell clones and peripheral blood T cells. J. Immunol. 49:2378.
46. Howard, M., and A. O'Garra. 1992. Biological properties of interleukin 10. Immunol. Today 13:198.
47. Ullman, K. S., J. P. Northrop, C. L. Verweij, and G. R. Crabtree. 1990. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu. Rev. Immunol. 8:421.
48. Lindsten, T., C. H. June, J. A. Ledbetter, G. Stella, and C. B. Thompson. 1989. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339.
49. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065.